Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 6/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670366 | 0.91 | MAPK14 (0.51) | PDK4NAMPTCNR1GRM5GRM1 | |
| SCHEMBL6866299 | 0.89 | MAPK14 (0.50) | PDK4NAMPTCNR1GRM5GRM1 | |
| SCHEMBL6670057 | 0.89 | MAPK14 (0.55) | PDK4MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6865882 | 0.88 | GRM5 (0.43) | PDK4NAMPTCNR1GRM5GRM1 | |
| SCHEMBL6668930 | 0.88 | MAPK14 (0.45) | PDK4NAMPTCNR1GRM5GRM1 | |
| SCHEMBL6669750 | 0.85 | PDK4 (0.42) | PDK4NAMPTCNR1GRM5GRM1 | |
| SCHEMBL6864402 | 0.80 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6670222 | 0.78 | MAPK14 (0.61) | PDK4NAMPTCNR1MAPK14HTR6 | |
| SCHEMBL6671657 | 0.78 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL30135250 | 0.78 | PDK4 (0.68) | PDK4NAMPTCNR1GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | PDK4 718/4885NAMPT 2914/4885CNR1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.